John P. Moore

Q: What Schools Are Affiliated With John P. Moore

John P. Moore is affiliated with the following schools: Rockefeller University, Baylor College of Medicine, Cornell University, New York University, University of Pennsylvania, Colorado State University, Harvard University, University of Amsterdam, Institute of Cancer Research, University of Kentucky, University of Oxford

John P. Moore's AcademicInfluence.com Rankings

John P. Moore

Biology

#1957

World Rank

#3155

Historical Rank

Virology

#82

World Rank

#85

Historical Rank

biology Degrees

Download Badge

Biology

Why Is John P. Moore Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John P. Moore is an American virologist and professor at Cornell University's Weill Cornell Medicine college, known for his research on HIV/AIDS. He previously worked at the Aaron Diamond AIDS Research Center. A former section editor of the Journal of General Virology, he is an outspoken critic of HIV/AIDS denialism, including the work of Peter Duesberg.

(See a Problem?)

John P. Moore's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 (1996) (1138)
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 (1996) (1120)
Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 (2001) (849)
HIV vaccine design and the neutralizing antibody problem (2004) (835)
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer (2013) (810)
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies (2013) (781)
Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro (2001) (724)
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield (2011) (691)
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer (2013) (678)
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding (1993) (677)
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (2014) (675)
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding (1991) (628)
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. (1990) (612)
The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 (2002) (570)
Inhibiting sexual transmission of HIV-1 infection (2003) (547)
A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure (2000) (542)
Co-receptors for HIV-1 entry. (1997) (537)
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. (2004) (527)
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 (2003) (500)
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 (1994) (483)
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. (2000) (470)
HIV-1 neutralizing antibodies induced by native-like envelope trimers (2015) (467)
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding (1995) (453)
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 (1995) (442)
Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 (2002) (438)
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation (1998) (422)
Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding (1997) (398)
Free cytoplasmic calcium concentration and the mitogenic stimulation of lymphocytes. (1983) (386)
A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells (1985) (382)
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. (1992) (363)
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer (1995) (353)
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein (1996) (351)
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. (2014) (350)
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding (1993) (346)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use (2002) (334)
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. (2014) (329)
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 (2013) (329)
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond (2016) (324)
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion (2005) (319)
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo (2001) (319)
The mechanism of the calcium signal and correlation with histamine release in 2H3 cells. (1984) (315)
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex (2014) (304)
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans (2008) (303)
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (2015) (301)
V3: HIV's switch-hitter. (2005) (299)
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates (1992) (297)
The entry of entry inhibitors: A fusion of science and medicine (2003) (294)
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. (1999) (286)
Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans (2013) (283)
The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS (2000) (280)
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies (1994) (280)
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody (2011) (267)
HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy (1998) (259)
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 (2013) (254)
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex (1997) (249)
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. (1999) (242)
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice (2015) (242)
Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue (2004) (240)
Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry (2003) (238)
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes (1996) (236)
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 (1994) (235)
Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry (1998) (235)
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization (1991) (234)
A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene (2015) (234)
Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 (1999) (234)
Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 (2001) (230)
Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate (2002) (229)
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination (2016) (227)
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans (1993) (224)
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor (2004) (221)
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines (1998) (220)
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein (2016) (217)
Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers (2009) (211)
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding (1990) (210)
The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C (2003) (209)
AIDS vaccine models: Challenging challenge viruses (2002) (206)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. (2007) (200)
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 (1994) (200)
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. (1999) (199)
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 (1997) (196)
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. (1995) (195)
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. (2015) (194)
Native‐like Env trimers as a platform for HIV‐1 vaccine design (2017) (193)
Open and Closed Structures Reveal Allostery and Pliability in the HIV-1 Envelope Spike (2017) (191)
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4 (1991) (188)
Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia (1994) (187)
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. (2008) (185)
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement (1996) (182)
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency (2009) (182)
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. (1994) (181)
Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage (1998) (181)
c-myc protein expression in untransformed fibroblasts. (1991) (180)
A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor (1999) (179)
The calcium signal and phosphatidylinositol breakdown in 2H3 cells. (1984) (177)
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). (2005) (177)
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation (2013) (176)
New targets for inhibitors of HIV-1 replication (2000) (176)
Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 (2001) (176)
Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro (1998) (173)
Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. (1992) (173)
Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells (2000) (172)
HIV-1 Membrane Fusion (2000) (171)
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures (2011) (170)
HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells (2007) (169)
Mitogens increase phosphorylation of phosphoinositides in thymocytes (1984) (168)
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. (2021) (168)
Temporal Analyses of Virus Replication, Immune Responses, and Efficacy in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine (1998) (167)
Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies (2014) (164)
Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein (2002) (161)
Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins (2002) (160)
Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection (2003) (157)
A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants (1999) (151)
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. (2010) (150)
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits (2014) (149)
HIV-1 Envelope Triggers Polyclonal Ig Class Switch Recombination through a CD40-Independent Mechanism Involving BAFF and C-Type Lectin Receptors1 (2006) (149)
The role of the V3 loop of gp120 in HIV infection. (1991) (148)
Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines (1998) (147)
Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 (1998) (142)
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. (2006) (140)
Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion (1999) (140)
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies (1994) (139)
Whither or Wither Microbicides? (2008) (139)
Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. (2016) (138)
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity (2015) (137)
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells (1992) (135)
A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials (2004) (133)
Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. (2015) (128)
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization (2017) (128)
Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542 (2004) (127)
Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop (1993) (126)
Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development (2001) (126)
Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits (2000) (126)
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity (2015) (125)
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B (1995) (124)
Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry? (1999) (124)
Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. (1989) (124)
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env (2015) (124)
Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C (2016) (123)
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens (2015) (122)
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains (1993) (122)
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. (2003) (121)
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo (2017) (120)
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability (2016) (119)
CD4-induced activation in a soluble HIV-1 Env trimer. (2014) (118)
Why do we not have an HIV vaccine and how can we make one? (1998) (118)
Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 (2005) (117)
The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity (1999) (117)
Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. (1990) (116)
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 (2009) (110)
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor (2005) (109)
The Use of Nonhuman Primate Models in HIV Vaccine Development (2008) (108)
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle (2019) (107)
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors (2009) (107)
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. (1995) (106)
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. (2010) (105)
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. (2007) (104)
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. (1998) (104)
Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer (2015) (102)
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? (2004) (98)
Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? (1992) (97)
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism (1997) (96)
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. (2016) (94)
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. (1990) (94)
Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1 (1994) (94)
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. (2004) (93)
Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein (2013) (92)
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers (2020) (92)
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen (2018) (91)
The role of CD4 in HIV binding and entry. (1993) (88)
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype (2000) (87)
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans (2021) (86)
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques (2018) (86)
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence (2019) (86)
Structural Characterization of Cleaved, Soluble HIV-1 Envelope Glycoprotein Trimers (2013) (86)
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. (2005) (86)
Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. (1993) (86)
Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage (1998) (86)
Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 (1998) (86)
Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry (2009) (85)
Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5 (2012) (85)
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off (1997) (85)
c-fos and c-myc gene activation, ionic signals, and DNA synthesis in thymocytes. (1986) (85)
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike (2015) (84)
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. (2010) (84)
Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation (1996) (83)
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens (2020) (83)
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? (2012) (82)
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 (1996) (81)
Calcium and cell proliferation. (1986) (80)
Synergistic signals in the mechanism of antigen-induced exocytosis in 2H3 cells: evidence for an unidentified signal required for histamine release (1987) (79)
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. (2000) (78)
HIV–1 neutralizing antibodies: How full is the bottle? (1999) (78)
Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site (2003) (78)
Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion (2003) (78)
Promote HIV Chemoprophylaxis Research, Don't Prevent It (2005) (77)
Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World? (2006) (76)
A sensitive and quantitative enzyme-linked immunosorbence assay for the c-myc and N-myc oncoproteins. (1987) (76)
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers (2017) (73)
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers (2015) (71)
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. (1989) (71)
Multiple CCR5 Conformations on the Cell Surface Are Used Differentially by Human Immunodeficiency Viruses Resistant or Sensitive to CCR5 Inhibitors (2011) (70)
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization (2020) (69)
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. (2009) (68)
Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques (2012) (68)
Highlights of the 2008 National Youth Gang Survey (2010) (68)
Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo (2000) (68)
COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds (2020) (68)
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. (2009) (66)
Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. (1988) (65)
HIV-1 Membrane Fusion: Targets of Opportunity (2000) (65)
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva (2021) (64)
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. (2007) (64)
Glycan-Dependent Immunogenicity of Recombinant Soluble Trimeric Hemagglutinin (2012) (63)
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. (2009) (63)
Extraction and recovery of inositol phosphates from tissues. (1987) (63)
Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. (2004) (62)
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. (2013) (62)
HIV type 1 coreceptors, neutralization serotypes, and vaccine development. (1997) (62)
Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion (2005) (62)
Animal models for microbicide studies. (2012) (61)
Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures (1994) (61)
Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. (1997) (60)
Structure of 2G12 Fab2 in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy (2014) (60)
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate (2017) (60)
Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. (2008) (60)
A Soluble Factor(s) Secreted from CD8+ T Lymphocytes Inhibits Human Immunodeficiency Virus Type 1 Replication through STAT1 Activation (2002) (59)
Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells (2003) (59)
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination (2018) (58)
Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant (1991) (58)
Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer (2016) (58)
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. (2011) (57)
Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. (1990) (57)
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. (2001) (57)
Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss (2007) (57)
Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. (1991) (56)
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes (2018) (55)
Partial Enzymatic Deglycosylation Preserves the Structure of Cleaved Recombinant HIV-1 Envelope Glycoprotein Trimers* (2012) (55)
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. (1998) (54)
Targeting HIV-1 envelope glycoprotein trimers to B cells using APRIL improves antibody responses (2011) (54)
Use of alternate coreceptors on primary cells by two HIV-1 isolates. (2005) (53)
A STEP into Darkness or Light? (2008) (52)
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120 (1994) (52)
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. (2006) (51)
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. (2007) (51)
Ca2+ and pH responses to sequential additions of mitogens in single 3T3 fibroblasts: correlations with DNA synthesis. (1988) (51)
Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array. (2012) (51)
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. (2000) (51)
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. (2000) (50)
Function of galanin in the anterior pituitary of estrogen-treated Fischer 344 rats: autocrine and paracrine regulation of prolactin secretion. (1998) (50)
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva (2021) (49)
Virus vaccines: proteins prefer prolines (2021) (49)
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. (2007) (49)
Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. (1992) (49)
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. (2007) (49)
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies (2014) (49)
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. (1998) (48)
Human B cells express IL-5 receptor messenger ribonucleic acid and respond to IL-5 with enhanced IgM production after mitogenic stimulation with Moraxella catarrhalis. (1996) (48)
Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. (2021) (48)
The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry Is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors (2004) (48)
Luteinizing Hormone-Releasing Hormone (LHRH) Biosynthesis and Secretion in Embryonic LHRH Neurons. (2000) (46)
The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. (1993) (46)
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates (2020) (46)
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission (2012) (46)
Independent evolution of Fc‐ and Fab‐mediated HIV‐1‐specific antiviral antibody activity following acute infection (2014) (45)
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers (2017) (45)
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. (2003) (45)
Highlights of the 1998 National Youth Gang Survey (1997) (45)
Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. (1993) (45)
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. (1992) (44)
Interaction of the CC-Chemokine RANTES with Glycosaminoglycans Activates a p44/p42 Mitogen-Activated Protein Kinase-Dependent Signaling Pathway and Enhances Human Immunodeficiency Virus Type 1 Infectivity (2002) (44)
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249 (2008) (44)
History of Street Gangs in the United States (2010) (43)
Urgently needed: a filter for the HIV-1 vaccine pipeline (2004) (43)
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo (2015) (43)
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. (2009) (42)
Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. (2015) (42)
Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage. (1993) (42)
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination (2021) (42)
Perspective: Research Highlights at the Aaron Diamond AIDS Research Center: The β-Chemokines, HIV Type 1 Second Receptors, and Exposed Uninfected Persons (1996) (41)
Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop (1994) (40)
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens (2020) (40)
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination (2021) (39)
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41 (2004) (39)
Predictors of Nonseroconversion after SARS-CoV-2 Infection (2021) (38)
Potent Induction of Antibody-Secreting B Cells by Human Dermal-Derived CD14+ Dendritic Cells Triggered by Dual TLR Ligation (2012) (38)
Macrophage-Tropic Simian/Human Immunodeficiency VirusChimeras Use CXCR4, Not CCR5, for Infections of Rhesus MacaquePeripheral Blood Mononuclear Cells and AlveolarMacrophages (2003) (37)
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. (2013) (37)
Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. (2009) (37)
Calcium signals and phospholipid methylation in eukaryotic cells. (1984) (37)
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens (2015) (36)
Calcium regulates inositol 1,3,4,5‐tetrakisphosphate production in lysed thymocytes and in intact cells stimulated with concanavalin A. (1987) (36)
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens? (2020) (35)
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells (2011) (35)
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. (2012) (35)
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. (2012) (35)
Rats selectively-bred for behavior related to affective disorders: proclivity for intake of alcohol and drugs of abuse, and measures of brain monoamines. (2008) (34)
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. (2004) (33)
Antigenic variation in gp120s from molecular clones of HIV-1 LAI. (1993) (33)
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment (1995) (33)
An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. (1997) (32)
A simple, efficient method for coupling DNA to cellulose. Development of the method and application to mRNA purification. (1981) (31)
Persistent Antibody Responses but Declining Cytotoxic T-Lymphocyte Responses to Multiple Human Immunodeficiency Virus Type 1 Antigens in a Long-Term Nonprogressing Individual with a Defective p17 Proviral Sequence and No Detectable Viral RNA Expression (1998) (31)
Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution* (2010) (31)
Use of G-Protein-Coupled and -Uncoupled CCR5 Receptors by CCR5 Inhibitor-Resistant and -Sensitive Human Immunodeficiency Virus Type 1 Variants (2013) (31)
HIV: A stamp on the envelope (2014) (30)
Early increases in phospholipid methylation are not necessary for the mitogenic stimulation of lymphocytes. (1982) (30)
Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro (2018) (30)
The Changing Boundaries of Youth Gangs (2002) (30)
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike (2020) (30)
Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. (1994) (30)
Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins (2015) (30)
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. (2007) (29)
Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. (1993) (29)
Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. (1991) (29)
Early Response Pattern Analysis of the Mitogenic Pathway in Lymphocytes and Fibroblasts (1985) (29)
Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers (2017) (29)
Topical microbicides become topical. (2005) (28)
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. (2011) (28)
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. (2008) (28)
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins (2018) (28)
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. (2006) (28)
Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes (2017) (27)
THE EFFECT OF FAMILY DISRUPTION ON ABORIGINAL AND NON-ABORIGINAL INMATES (2001) (27)
Reintegration of Indigenous prisoners (2008) (26)
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. (2007) (26)
Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line? (2003) (26)
Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies (2019) (26)
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers (2017) (25)
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. (2006) (24)
HIV Molecular Immunology 2001 (2001) (24)
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles (2020) (24)
The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. (1996) (23)
Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. (2018) (23)
What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure? (2015) (22)
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. (2014) (22)
Galanin within the normal and hyperplastic anterior pituitary gland: localization, secretion, and functional analysis in normal and human growth hormone-releasing hormone transgenic mice. (1999) (22)
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. (2012) (22)
A Chimeric HIV-1 Envelope Glycoprotein Trimer with an Embedded Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Domain Induces Enhanced Antibody and T Cell Responses* (2011) (21)
High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique. (1989) (21)
Science fiction, critical frontiers (2000) (21)
Galanin gene expression is increased in the anterior pituitary gland of the human growth hormone-releasing hormone transgenic mouse. (1994) (21)
Luteinizing hormone-releasing hormone (LHRH) biosynthesis and secretion in embryonic LHRH. (2000) (21)
Faculty Opinions recommendation of CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. (2003) (21)
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients (2021) (21)
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health (2021) (20)
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide (2019) (20)
A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. (1993) (19)
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency (2020) (19)
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin (2019) (19)
HIV-1 envelope protein gp120 expression by secretion in E. coli: assessment of CD4 binding and use in epitope mapping. (1990) (19)
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. (2001) (19)
Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies. (1990) (19)
A Profile of Federal Offenders Designated as Dangerous Offenders or Serving Long-Term Supervision Orders (2002) (18)
Differential induction of c-fos and c-myc by cyclic AMP in Swiss 3T3 cells: significance for the mitogenic response. (1988) (18)
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. (2012) (18)
A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1 (1993) (18)
HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex. (2007) (17)
Dhanier Ft Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp 41 (2009) (17)
Another HIV vaccine failure: where to next? (2013) (17)
Novel Strain of the Chronic Wasting Disease Agent Isolated From Experimentally Inoculated Elk With LL132 Prion Protein (2020) (16)
Role of a Putative gp41 Dimerization Domain in Human Immunodeficiency Virus Type 1 Membrane Fusion (2009) (16)
SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses (2011) (16)
The "In Search of Your Warrior" Program for Aboriginal Offenders: A Preliminary Evaluation (2005) (16)
Determining neutralization serotypes of HIV type 1 by neural networks. (1996) (16)
HIV tropism and CD4+ T-cell depletion (2002) (15)
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers (2017) (15)
Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers (2013) (15)
Kinetics of primary and secondary stimulation of the mRNA for APOVLDL-II, a major yolk protein, in the cockerel liver by estrogen. (1983) (15)
SARS-CoV-2 Vaccines: ‘Warp Speed’ Needs Mind Melds not Warped Minds (2020) (15)
HIV-1 entry inhibitor entrances. (2004) (15)
MtTW-10 pituitary tumor cells: galanin gene expression and peptide secretion. (1993) (14)
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM (2021) (14)
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. (2014) (14)
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines (2012) (14)
High levels of the c-myc protein in cell lines of Bloom's syndrome origin. (1989) (14)
Changes in the V 3 region of gp 120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR 5 Delta 32 heterozygote (2007) (13)
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients (2021) (13)
Chemoattractants attract HIV researchers (1996) (13)
Stabilization of the V2 loop improves the presentation of V2 loop–associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers (2019) (13)
Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells (2013) (12)
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers (2020) (12)
CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro. (1992) (12)
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens (2019) (12)
Complementation of human immunodeficiency virus glycoprotein mutations in trans. (1992) (11)
Demonstration of peripheral fucose units in N-linked glycans of human immunodeficiency virus type 1 gp 120: effects on glycoprotein conformation (1997) (11)
The impact of individual consultation on the teaching of younger versus older faculty (2002) (11)
Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach. (1993) (11)
Erratum“Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?” [Virology 323 (2004) 1–8] (2004) (11)
Enhancement of alpha-helix mimicry by an alpha / beta-peptide foldamer via incorporation of a dense ionic side-chain array. (2012) (11)
Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. (2000) (11)
Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells (2019) (11)
HIV Molecular Immunology 2014 (2015) (10)
Galanin gene expression in radiothyroidectomy-induced thyrotroph adenomas. (1996) (10)
Large effects of preparative techniques on lymphocyte cyclic AMP content. (1983) (10)
Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists (2012) (10)
Resistance to CCR 5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp 41 (2009) (9)
HIV-1 Env antibodies: are we in a bind or going blind? (2012) (9)
Immunological probes in the analysis of myc protein expression. (1988) (9)
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes (2019) (9)
Kinetics of the HIV-CD4 interactions and virus-cell fusion. (1992) (9)
Large induction of c-Myc is not essential for the mitogenic response of Swiss 3T3 fibroblasts. (1997) (9)
HIV Molecular Immunology 2015 (2016) (9)
Dissociation of c-fos induction from protein kinase C-independent mitogenesis in Swiss 3T3 cells. (1989) (8)
Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines. (1991) (8)
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates (2021) (8)
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients (2020) (8)
Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4. (1991) (8)
Detecting SIV gp120 and its interaction with soluble CD4 by ELISA. (1993) (8)
AIDS vaccines: On the trail of two trials (2002) (8)
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers (2020) (7)
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide (2019) (7)
Errors in Celia Farber's March 2006 article in Harper's Magazine (2006) (7)
Conformation of the HIV-1 gp 120 envelope glycoprotein. (1996) (7)
Inef fi cient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR 5 complex at low cell surface CCR 5 densities (2009) (7)
High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination (2021) (6)
The Needs of Métis Offenders in Federal Correctional Facilities in British Columbia (2003) (6)
Immunological incompetence in AIDS. (1991) (6)
Recognition of HIV‐inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664 (2017) (6)
The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization (2021) (6)
A sensitive enzyme-linked immunosorbence assay for the c-fos and v-fos oncoproteins. (1988) (6)
The dangers of denying HIV (2009) (6)
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. (2015) (6)
Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line. (1990) (5)
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env (2022) (5)
Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat. (2010) (5)
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses (2022) (5)
Don't Sell Social Science Short (2006) (5)
An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells (2013) (5)
Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. (2005) (5)
SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers (2019) (5)
Autoantibodies Induced by Chimeric Cytokine-HIV Envelope Glycoprotein Immunogens (2014) (5)
Vitro Immunodeficiency Virus Type 1 Is Rare In Pediatric Isolates of Human Non-Syncytium-Inducing Adult and Use of Coreceptors Other Than CCR 5 by (1998) (5)
A Plea for Justice for Jailed Medical Workers (2006) (5)
Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers (2021) (5)
Publishing: Journals, do your own formatting (2017) (5)
Corrigendum to “Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function” [Virology 401 (2010) 236–247] (2010) (5)
Antigenicity of the HIV-2 V3 loop. (1992) (4)
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles (2021) (4)
The bivalent-cation dependence of phosphatidylinositol synthesis in a cell-free system from lymphocytes. (1983) (4)
Pê Sâkâstêw Centre: An In-Depth Examination of a Healing Lodge for Federally Incarcerated Offenders (2007) (4)
C‐fos gene activation in murine thymocytes by a mechanism independent of protein kinase C or a Ca2+ signal (1988) (4)
Mitogen-stimulated activation of the Na+/H+ antiporter does not regulate S6 phosphorylation or protein synthesis in murine thymocytes or Swiss 3T3 fibroblasts. (1990) (4)
Human Immunodeficiency Virus Type 1 Mutants That Escape Neutralization by Human Monoclonal Antibody IgG 1 b 12 (1997) (4)
Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein (2021) (4)
Manitoba: An Examination of the Program Needs of Métis Offenders in Federal Correctional Facilities (2004) (4)
Pre-treatment with Depo-Provera modifies the pharmacokinetics of CMPD167 in rhesus macaques following vaginal ring administration (2010) (4)
Online submission makes authors do all the work (2005) (3)
The early mitogenic pathway in mouse thymocytes: an analysis of the dual signal hypothesis. (1987) (3)
Inhibition of HIV-1 replication in alveolar macrophages by adenovirus gene transfer vectors. (2002) (3)
The Needs of Inuit Offenders in Federal Correctional Facilities (2004) (3)
Structural Constraints Det ermine the Glycosylation of HIV-1 Envelope Trimers Graphical (2015) (3)
Program and Service Needs of Federally Incarcerated Métis Offenders in Saskatchewan (2004) (3)
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody (2022) (2)
Corrigendum to "V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc" [Virology 427 (2012) 158-165] (2012) (2)
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons (2022) (2)
Pituitary hormone gene expression and secretion in human growth hormone-releasing hormone transgenic mice: focus on lactotroph function. (2000) (2)
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor (2004) (2)
Monoclonal antibodies to HIV-1 gp120: a request. (1993) (2)
GTPγS inhibits early c‐myc protein accumulation but not DNA synthesis in Swiss 3T3 fibroblasts (1990) (2)
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits (2014) (2)
Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission (2006) (2)
Asthma 17q21 polymorphism associates with decreased risk of COVID‐19 in children (2022) (2)
Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells. (2005) (2)
Faculty Opinions recommendation of Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. (2002) (2)
High-resolution mapping of the neutralizing and binding specificities of polyclonal rabbit serum elicited by HIV Env trimer immunization (2020) (1)
HIV denialists will exploit any journal's tolerance (2004) (1)
The Cambrian Conundrum: Early Divergence and Later Ecological Success in the Early History of Animals (2011) (1)
Differential Use of CCR 5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR 5 Antagonists (2012) (1)
HIV-1 SOSIP envelope glycoprotein 2 (2013) (1)
D-102 The potency of broadly neutralizing antibodies directly relates to their ability to recognize the closed pre-fusion form of HIV Env (2014) (1)
Misconduct: don't penalize the honest majority of scientists (2010) (1)
Reducing the immunodominant non-neutralizing V 3 response to HIV-1 Env trimers (2017) (1)
HIV infactivity (1991) (1)
Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers (2021) (1)
Speaking Out About U.S. Science Output (2007) (1)
United States v. James T. Labat, 915 F.2d 603 (10th Cir. September 28, 1990) (1990 U.S. App. LEXIS 17155) (1991) (1)
The invisible cure: Africa, the West, and the fight against AIDS (2007) (1)
Childhood Experiences of Aboriginal Offenders (2004) (1)
HIV Research for Prevention HIV R4P (2014) (0)
D-103 Studies on native-like SOSIP.664 trimers and other forms of Env (2016) (0)
HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies (2022) (0)
The Fitness Cost to Human Immunodeficiency Virus Type 1 of Escaping From a Small Molecule CCR5 Inhibitor (2005) (0)
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies (2014) (0)
by Monoclonal Antibodies to CCR5 gp120 Binding, and CC-Chemokine Activity Immunodeficiency Virus Type 1 Fusion, Differential Inhibition of Human (2012) (0)
Bristol-Myers Squibb Announces Awards (2004) (0)
P156 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, DEMONSTRATES EFFICACY IN PATIENT-DERIVED PBMC IN VITRO AND IN AN IN VIVO T CELL TRANSFER MODEL OF CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) (2020) (0)
Probing structural dynamics by mass spectrometry provides new insights into HIV's structural and antigenic diversity (2022) (0)
Faculty Opinions recommendation of CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? (2002) (0)
Complex of 3-alpha bound to gp41-5 (2012) (0)
D-105 Immunogenicity of native-like SOSIP.664 trimers (2014) (0)
Faculty Opinions recommendation of Diversity of receptors binding HIV on dendritic cell subsets. (2002) (0)
MINIREVIEW Genetic Subtypes, Humoral Immunity, and Human Immunodeﬁciency Virus Type 1 Vaccine Development (2001) (0)
Bone marrow transplant muffles HIV (2009) (0)
Reintegrating Indigenous offenders: recidivism among Indigenous Australians who have been imprisoned (2006) (0)
HIV-1 Coreceptors and Viral Tropism (1999) (0)
UvA-DARE ( Digital Academic Repository ) Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp 120 and gp 41 (2017) (0)
Faculty Opinions recommendation of DNA deamination mediates innate immunity to retroviral infection. (2003) (0)
through STAT 1 Activation Immunodeficiency Virus Type 1 Replication Lymphocytes Inhibits Human T + A Soluble Factor ( s ) Secreted from CD 8 (2001) (0)
Author response: High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination (2021) (0)
C-101 Production and properties of SOSIP trimers (2018) (0)
D-101 CryoEM Studies of HIV-1 Envelope Glycoprotein (2014) (0)
Antibody to the gpl20 V2 Loop (2003) (0)
Chapter 9 An HIV elite neutralizer as a blueprint for the induction of neutralizing antibodies (2016) (0)
Role of a putative gp 41 dimerization domain in HIV-1 membrane fusion (2009) (0)
Complex of 4-alpha/beta bound to gp41-5 (2012) (0)
Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers (2021) (0)
Pharmacokinetics of microbicides formulated in sustained delivery devices for protection from vaginal SIV/SHIV transmission in macaques (2011) (0)
immunodeficiency virus type 1 . seroconversion to human antibody response during Development of the anti-gp 120 (0)
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization (2023) (0)
Soluble CD4-gpl20 Complex Preferentially Induces Neutralizing Anti-Human Immunodeficiency Virus (0)
Faculty Opinions recommendation of Effect of coinfection with GB virus C on survival among patients with HIV infection. (2002) (0)
SOLUBLE CD4 BINDING TO HIV-1 VIRIONS CAUSES GP120 TO DISSOCIATE FROM GP41 (1991) (0)
Faculty Opinions recommendation of Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys. (2003) (0)
STRUCTURAL-ANALYSIS OF THE HIV-1 ENVELOPE GLYCOPROTEIN GP120 (1993) (0)
A case for research consortia to accelerate vaccine candidate discovery: identification of a stable antigenic HIV-1 Clade A Env candidate (P6370) (2013) (0)
118 Inhibiting CCR5 in vitro and in vivo (2011) (0)
SOSIP Envelope Glycoprotein Aggregation of Soluble, Cleaved HIV-1 Influences on Trimerization and (2014) (0)
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence (2019) (0)
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines (2012) (0)
HIV-1 infection of CD4+ cells. immunodeficiency virus type 1 (HIV-1) and in the envelope glycoproteins of human soluble CD4-induced conformational changes A monoclonal antibody to CD4 domain 2 blocks (2013) (0)
E111 Vaccine-microbicide combination studies in a rhesus macaque vaginal transmission model (2013) (0)
UvA-DARE ( Digital Academic Repository ) HIV-1 envelope trimer fusion proteins and their applications (2016) (0)
Dendritic Cells Responses by TLR9-Activated Plasmacytoid HIV-1 gp120 Impairs the Induction of B Cell (2012) (0)
Beta testing the monkey model (2021) (0)
Response : Receptor-Mediated Activation of Immunodeficiency Viruses in Viral Fusion (1991) (0)
Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Citation (2016) (0)
BAFF and C-Type Lectin Receptors CD 40-Independent Mechanism Involving Switch Recombination through a HIV-1 Envelope Triggers Polyclonal Ig Class (2006) (0)
CCR5 inhibitors as vaginal microbicides (2010) (0)
HIV TARGET-CELL INTERACTIONS (1990) (0)
Immunodeficiency Virus Type 1 Variants Inhibitor-Resistant and -Sensitive Human CCR5 Receptors by CCR5 Use of G-Protein-Coupled and -Uncoupled (2014) (0)
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. (1992) (0)
of Coreceptor Usage Sera from Infected Individuals Is Independent of Human Immunodeficiency Virus Type 1 by Evidence that Antibody-Mediated Neutralization (1998) (0)
Human Immunodeficiency Virus Type 1 Neutralization Is Determined by Epitope Exposure on the gp120 Oligomer By Quentin (2003) (0)
Enhances Viral Infectivity Signal Transduction Pathway That Glycosaminoglycans and Also Activates a Virus Type 1 to Target Cells via Attachment of Human Immunodeficiency The CC-Chemokine RANTES Increases the (1999) (0)
, Albert Trimers Soluble HIV-1 Envelope Glycoprotein Structural Characterization of Cleaved (2013) (0)
GTP gamma S inhibits early c-myc protein accumulation but not DNA synthesis in Swiss 3T3 fibroblasts. (1990) (0)
United States v. Billy E. Creech, 901 F.2d 861 (10th Cir. April 20, 1990) (1990 U.S. App. LEXIS 6060) (1990) (0)
In Search of Congress: Why an Executive Branch Search of a Congressional Office Violates the Speech or Debate Clause and How Congress Should Respond (2007) (0)
Recombinant gp 120 Subunit Vaccines Virus Type 1 while Participating in Trials of Persons Infected by Human Immunodeficiency Immunological and Virological Analyses of (1998) (0)
Detection of gp120 hiv 1 and antibodies to defined regions of gp120 in human serum correlation with hiv 1 neutralization (1989) (0)
Alternative strategies for antagonism of IL-5 (2005) (0)
Selection and preliminary characterization of variant lines of a murine macrophage tumor resistant to the antiproliferative effects of phorbol esters. (1990) (0)
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. (1992) (0)
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions (2023) (0)
Eliciting broadly neutralizing antibodies to human immunodeficiency virus could bring closer the goal of a successful AIDS vaccine. Here the International AIDS Vaccine Initiative Neutralizing Antibody Consortium discusses current approaches to overcome the problems faced. (2004) (0)
Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral Immunodeficiency (2020) (0)
Erwin Success in the Early History of Animals The Cambrian Conundrum : Early Divergence and Later Ecological (2011) (0)
Microscopyn Single-Particle Electron Soluble and Fully Glycosylated HIV-1 Env in Complex with 2 Structure of 2G12 Fab (2014) (0)

This paper list is powered by the following services:

Other Resources About John P. Moore

en.wikipedia.org

What Schools Are Affiliated With John P. Moore?

John P. Moore is affiliated with the following schools: